XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Segment and Geographic Data (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Segment Results
Three Months
2025
2024
MedSurg and Neurotechnology
$3,511
$3,097
Orthopaedics
2,355
2,146
Net sales
$5,866
$5,243
MedSurg and Neurotechnology
$1,321
$1,238
Orthopaedics
629
591
Cost of sales
$1,950
$1,829
MedSurg and Neurotechnology
$226
$195
Orthopaedics
140
134
Segment research, development and
engineering expenses
$366
$329
MedSurg and Neurotechnology
$937
$763
Orthopaedics
847
751
Segment selling, general and
administrative expenses
$1,784
$1,514
MedSurg and Neurotechnology
$57
$54
Orthopaedics
98
108
Segment depreciation and amortization
$155
$162
Corporate and Other
$39
$40
Amortization of intangible assets
167
153
Total depreciation and amortization
$361
$355
MedSurg and Neurotechnology
$970
$847
Orthopaedics
641
562
Segment operating income
$1,611
$1,409
Items not allocated to segments:
Corporate and Other
$(267)
$(263)
Inventory stepped up to fair value
(34)
Acquisition and integration-related charges
(185)
13
Amortization of intangible assets
(167)
(153)
Structural optimization and other special
charges
(41)
(11)
Goodwill and other impairments
(35)
(3)
Medical device regulation
(12)
(13)
Recall-related matters
(33)
(5)
Regulatory and legal matters
(2)
Consolidated operating income
$837
$972
Segment Assets
March 31
December 31
2025
2024
Assets:
MedSurg and Neurotechnology
$26,912
$23,115
Orthopaedics
17,878
18,507
Total segment assets
$44,790
$41,622
Corporate and Other
1,216
1,349
Total assets
$46,006
$42,971
Sales and Other Financial Information by Business Segment
Segment Capital Spending
Three Months
2025
2024
Purchases of property, plant and
equipment:
MedSurg and Neurotechnology
$48
$41
Orthopaedics
34
65
Total segment purchases of property, plant
and equipment
$82
$106
Corporate and Other
41
61
Total purchases of property, plant and
equipment
$123
$167